Antiviral İlaçlar
Tarih boyunca viral hastalıklar epidemiler veya pandemiler meydana getirerek, insanoğlunu ve onunla etkileşim
Antiviral Drug
Throughout history, viral diseases have always threatened lives of all humans and living beings in contact with them causing epidemics and pandemics. These epidemics that caused death or destruction of millions of living beings also brought about the need for protection and treatment. Technological and health opportunities that started to develop at the beginning of the 20st century made it possible to convey studies and research on treatment of viral diseases. In this composition, information has been provided about antiviral agents developed to be used in treatment of viral infections threatening human and animal health.
___
- Adalsteinsson JA, Pan M, Kaushik S, Ungar J, (2018).
Foscarnet-induced genital lesions: An overview with a case
report. Dermatol Reports.10, 12-13.
- Adams J, Patel N, Mankaryous N, Tadros M, Miller CD,
(2010). Nonnucleoside Reverse Transcriptase Inhibitor
Resistance and the Role of the Second-Generation Agents.
Ann Pharmacother. 44, 157–165.
- Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA,
(2018). Proteases and protease inhibitors in infectious dis-
eases. Med Res Rev. 38, 1295-1331.
- Air GM, (2012), İnfluenza neuraminidase. İnfluenza Other
Respir Virus. 6,245-256.
- Al-Badr AA, Ajarim TDS, (2018). Ganciclovir. Brittin HG.
Eds. Profiles of Drug Substances, Excipients and Related
Methodology vol 43. Academic Press Inc, USA, 1-208.
- Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini
J, Snoeck R, (2005). Susceptibilities of several clinical
varicella-zoster virus (VZV) isolates and drug-resistant
VZV strains to bicyclic furano pyrimidinenucleosides,
Antimicrob Agents Chemother. 49, 1081–1086.
- Angus P, Vaughan R, Xıong S, Yang H, Delaney W, Gibbs C,
Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz
A, Locarnini S, (2003). Resistance to Adefovir Dipivoxil
Therapy Associated With the Selection of a Novel Mutation
in the HBV Polymerase. Gastroenterology. 125, 292-297.
- Arslan U, Ural O, Fındık D, (2008). Lamivudin tedavisi alan
kronik hepatit B olgularında inno-lipa HBV DR yöntemi ile
saptanan YMDD motif değişiklikleri, Mikrobiyol Bul. 42,
445-450.
- Berkhout B, Eggink D, Sanders RW, (2012). Is there a future
for antiviral fusion inhibitors.
- Białek-Pietras M, Olejniczak AB, Paradowska E, Studzinska
M, Jabłonska A, Lesnikowski ZJ, (2018). Synthesis, suscep-
tibility to enzymatic phosphorylation, cytotoxicity and in
vitro antiviral activity of lipophilic pyrimidine nucleoside/
carborane conjugates. J Organomet Chem. 865, 166-172.
- Chang T, Gish R, De Man R, (2006). A comparison of ente-
cavir and lamivudine for HBeAg-positive chronic hepatitis
B. N. Engl. J. Med. 354, 1001-1010.
12. Charpentier C, Camacho R, Ruelle J, Eberle J, Gurtler L,
Pironti A, Sturmer M, Brun-Vezinet F, Kaiser R, Descamps
D, Obermeier M, (2015). HIV-2EU-supporting standard-
ized HIV-2 drug-resistance interpretation in Europe: an
update. Clin Infect Dis. 61, 1346-1347.
- . Chou TY, Hong BY, (2014). Ganciclovir ophthalmic gel
%0.15 for the treatment of acute herpetic keratitis: back-
ground, effectiveness, tolerability, safety, and future appli-
cations. Ther Clin Risk Manag. 10, 665–681.
- Cihlar T, Ray AS, (2010). Nucleoside and nucleotide HIV
reverse transcriptase inhibitors: 25 years after zidovudine.
Antiviral Res. 85,39-58. Curr OpinVirol. 2, 50-59.
15. Curran M, Noble S, (2001). Valganciclovir. Drugs. 61,
1145–1150.
- D’Cruz OJ, Uckun FM, (2006). Dawn of non-nucleoside
inhibitor-based anti-HIV microbicides. J Antimicrob
Chemother. 57,411–423.
- . Das K, Arnold E, (2013). HIV-1 reverse transcriptase and
antiviral drug resistance. Part 1. Curr Opin Virol. 3,111-
118.
- De Clercq E, (2009). Looking back in 2009 at the dawning
of antiviral therapy now 50 years ago: An historical per-
spective. Adv Virus Res. 73, 1-53.
- De Clercq E, Li G, (2016). Approved antiviral drugs over
the last 50 years. Clin Microbiol Rev. 29, 695-747.
20. De Clercq, (2004). Discovery and development of BVDU
(brivudin) as a therapeutic for the treatment of herpes zos-
ter. Biochem Pharmacol. 68, 2301-2315.
- De Leuw P, C Stephen, (2018). Protease inhibitor therapy
for hepatitis C virus-infection. Expert Opin Pharmacother.
19, 577–587.
- De Miguel R, Montejano R, Stella-Ascaris N, Arribas JR,
(2017). A safety evaluation of raltegravir for the treatment
of HIV. Expert Opin Drug Saf. 17, 217-223.
- Dienstag JL, Goldin RD, Heathcote EJ, Hann HWL,
Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff
ER, (2003). Histological Outcome During Long-term
Lamivudine Therapy. Gastroenterology. 124, 105-17.
- Dingens AS, Arenz D, Overbaugh J, Bloom JD, (2018).
Massively parallel profiling of HIV-1 resistance to the fu-
sion inhibitor enfuvirtide. BioRxiv 472746, Erişim tarihi:
06.12.2018.
- Diogo JV, Novo SG, Gonzalez MJ, Ciancia M, Bratanich
AC, (2015). Antiviral activity of lambda-carrageenan pre-
pared from red seaweed (Gigartina skottsbergii) against
BoHV-1 and SuHV-1, Res Vet Sci. 98,142-144.
26. Este JA, Telenti A, (2007). HIV entry inhibitors. Lancet,
370, 81-88.
- Fontenelle JP, Powell CC, Veir KJ, Radecki SV, Lappin
RM, (2008). Effect of topical ophthalmic application of
cidofovir on experimentally induced primary ocular feline
herpesvirus-1 infection in cats. Am J Vet Res. 69, 289-293.
- . Groth DA, Contreras MT, Kado-Fong HK, Nguyen KQ,
Thomasy SM, Maggs DJ, (2014). In vitro cytotoxicity and
antiviral efficacy against feline herpesvirus type 1 of fam-
ciclovir and its metabolites. Vet Ophthalmol. 17, 268-274.
- Hamann M, Hill R, Roggo S, (2007). Marine natural prod-
ucts. Key advances to the practical application of this re-
source in drug development. Chimia. 61, 313-321.
- . Hammer KDP, Dietz J, Lo TS, Johnson ME, (2018). A sys-
tematic review on the efficacy of topical acyclovir, penci-
clovir, and docosanol for the treatment of herpes simplex
labialis. EMJ Dermatol, 6, 118-123.
- Hayashi N, Nakamuta M, Takehara T, Kumada H, Takase A,
Howe AY, Ludmerer SW, Mobashery N, (2016). Vaniprevir
plus peginterferon alfa-2b and ribavirin in treatment-naive
Japanese patients with hepatitis C virus genotype 1 infec-
tion: a randomized phase III study. Gastroenterology. 51,
390-403.
- Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP,
Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula
G, Danovich RM, Witmer MV, Wilson KA, Tussey L,
Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro
DR, Emini EA, Shiver JW (2004). Integrase inhibitors and
cellularimmunity suppress retroviral replication in rhesus
macaques. Sci.305, 528-532.
- Heim MH, (2013). 25 years of interferon-based treatment
of chronic hepatitis C: An epoch coming to an end. Nat Rev
Immunol. 13, 535-542.
- Hussein İTM, Menashy RV, Field HJ, (2008). Penciclovir is
a potent inhibitor of feline herpesvirus-1 with susceptibility
determined at the level of virus-encoded thymidine kinase.
Antiviral Res. 3, 268-274.
- . Ikeda T, Tennyson R, Walker SN, Harris RS, McNaughton
B (2019): Evolved Proteins Inhibit Entry of Enfuvirtide-
Resistant HIV-1, ACS Infect Dis (Article ASAP), DOI:
10.1021/acsinfecdis.8b00362.
- Ison MG, (2013). Clinical use of approved influenza an-
tivirals: therapy and prophylaxis. Influenza Other Respi
Viruses. 7, 7–13.
- Jacob A, Sood R, Chanu KV, Bhatia S, Khandia R,
Pateriya AK, Nagarajan S, Dimri U, Kulkarni DD, (2016).
Amantadine resistance among highly pathogenic avian in-
fluenza viruses (H5N1) isolated from India, Microb Pathog.
91, 35-40.
- Kamali A, Holodniy M, (2013). Influenza treatment and
prophylaxis with neuraminidase inhibitors: a review. İnfect
Drug Resist. 6, 187-198.
39. Kozakov D, Chuang GY, Beglov D, Vajda S, (2010). Where
does amantadine bind to the influenza virus M2 proton
channel ?. Trends Biochem Sci. 35,471-475.
- Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang
Y, Chen Y, Heathcote JE, Resenack J, Bzowej N, Naoumov
NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z,
Chao G, Constance BF, Brown NA, (2007). Telbivudine
versus Lamivudine in Patients with Chronic Hepatitis B.
New Eng J Med. 357, 2576-2588.
- Leung DT, Sacks SL, (2004). Docosanol: a topical anti-
viral for herpes labialis. Expert Opin Pharmacother. 5,
2567–2571.
- Liang R, Li H, Swanson JM, Voth GA, (2014). Multiscale
simulation reveals a multifaceted mechanism of proton per-
meation through the influenza A M2 proton channel. Proc
Natl Acad Sci USA. 111, 9396–9401.
- Lv Z, Chu Y, Wang Y, (2015). HIV protease inhibitors: a
review of molecular selectivity and toxicity. HIV/AIDS
(Auckl). 7, 95-104.
- Maes R, (2012). Felid Herpesvirus Type 1 Infection in Cats.
A Natural Host Model for Alphaherpesvirus Pathogenesis.
Int Sch Res Net Vet Sci, 1-14.
- Maggs DJ, (2005). Update on Pathogenesis, Diagnosis, and
Treatment of Feline Herpesvirus Type 1, Clin Tech Small
Anim Pract. 20, 94-101.
46. Maggs DJ, Clarke HE, (2004). In vitro efficacy of ganci-
clovir, cidofovir, penciclovir, foscarnet, idoxuridine, and
acyclovir against feline herpesvirus type-1. Am J Vet Res.
65, 399-403.
- Mahmoud S, Hasabelnaby S, Hammad SF, Sakr TM, (2018).
Antiviral Nucleoside and Nucleotide Analogs: A Review. J
Adv Pharm Res. 2, 73-88.
- McKimm-Breschkin JL, (2013). Influenza neuraminidase
inhibitors: antiviral action and mechanisms of resistance.
İnfluenza Other Respir Virus. 7, 25-36.
- Messina JP, Humphreys I, Flaxman A, Brown A, Cooke
GS, Pybus OG, Barnes E, (2015). Global distribution and
prevalence of hepatitis C virus genotypes. Hepatology. 61,
77–87.
- Moscana A, (2005). Neuraminidase Inhibitors for Influenza.
New Eng J Med. 353, 1363-1373.
51. Mouscadet JF, Tchertanov L, (2009). Raltegravir: molecu-
lar basis of its mechanism of action. Eur J Med Res. 14,
5–16.
- Nováková L, Pavlík, J. Chrenková L, Martinec O, Červený
L, (2018). Current antiviral drugs and their analysis in
biological materials—Part I: Antivirals against respiratory
and herpes viruses. J Pharm Biomed Anal. 147, 400–416.
- Patel P, Louie S, (2018). Drug Interactions in HIV: Protease
and Integrase Inhibitors. Pai M, Kiser J, Gubbins P,
Rodvold K eds. Drug Interactions in Infectious Diseases:
Antimicrobial Drug Interactions Fourth edition. Humana
Press, Cham. p.255-295.
- Patel, IH, Zhang X, Nieforth K, Salgo M, Buss N, (2005).
Pharmacokinetics, pharmacodynamics and drug interac-
tion potential of enfuvirtide. Clin Pharmacokinet. 44, 175-
186.
- Perry CM, (2010). A Review of its Use in the Management
of CCR5-Tropic HIV-1 Infection. Drugs. 70, 1189-1213.
56. Pielak RM, Schnell JR, Chou JJ, (2009). Mechanism of
drug inhibition and drug resistance of influenza A M2 chan-
nel, Proc Nat Acad Sci. 106, 7379-7384.
- . Poole CL, James SH, (2018). Antiviral therapies for her-
pesviruses: Current agents and new direction. Clin Thera.
40, 1282-1298.
58. Quashie PK, Sloan RD, Wainberg MA, (2012). Novel thera-
peutic strategies targeting HIV integrase. BMC Med. 10,
1-11.
- . Rad TM, Saghaie L, Fassihi A, (2019). HIV-1 Entry
Inhibitors: A Review of Experimental and Computational
Studies. Chem Biodiversty. 15, e1800159.
- Razonable RR, (2011). Antiviral Drugs for Viruses Other
Than Human Immunodeficiency Virus. Mayo Clin Proc. 86,
1009–1026.
- Rokx C, Rijnders BJA, (2015). Evidence gathered from
randomized clinical trials and observational studies on the
equivalence of emtricitabine and lamivudine. Clin Infect
Dis. 60, 1732–1733
- Sacks SL, Thisted RA, Jones TM, Barbarash RA, Mikolich
DJ, Ruoff GE, Jorizzo JL, Gunnill LB, Katz DH, Khalil
MH, Morrow PR, Yakatan GJ, Pope LE, Berg JE, Docosanol
10% Cream Study Group, (2001). Clinical efficacy of topi-
cal docosanol 10% cream for herpes simplex labialis: a
multicenter, randomized, placebo-controlled trial. J Am
Acad Dermatol.45, 222-230.
- Samson M, Pizzorno A, Abed Y, Boivin G, (2013). Influenza
virus resistance to neuraminidase inhibitors. Antiviral Res.
98,174–185.
- Sancho-Ruiz A, Sheldon J, Soriano V, (2007). Telbivudine:
a new option fort he treatment of chronic hepatitis B. Expert
Opin. Biol. Ther. 7, 751-761.
- Sandmeyer LS, Keller CB, Bienzle D, (2005). Effects of
interferon-α on cytopathic changes and titers for feline her-
pesvirus-1 in primary cultures of feline corneal epithelial
cells. Am J Vet Res. 66, 210-216.
- . Sarrazin C, (2016). The importance of resistance to direct
antiviral drugs in HCV infection in clinical practice. J
Hepatol. 64, 486–504.
67. Schoggins JW, (2018). Recent advances in antiviral in-
terferon-stimulated gene biology. F1000Research. 7: 309.
Erişim tarihi: 28.03.2019.
- Sebbag L, Thomasy SM, Woodward PA, Heather KK,
Maggs DJ, (2016). Pharmacokinetic modeling of penciclo-
vir and BRL42359 in the plasma and tears of healthy cats to
optimize dosage recommendations for oral administration
of famciclovir. Am J Vet Res. 77, 833-845.
- Segovia CM, Chacra W, Gordon SC, (2012). Adefovir
dipivoxil in chronic hepatitis B: history and current uses.
Expert Opin Pharmacother. 13, 245-254.
- Seley-Radtke KL, Yates MK, (2018). The evolution of
nucleoside analogue antivirals: A review for chemists and
non-chemists. Part 1: Early structural modifications to the
nucleoside scaffold. Antivir Res. 154, 66–86.
- Siebeck N, Hurley JD, Garcia M, Greene CE, Köstlin RG,
Moore AP, Dietrich UM, (2006). Effects of human recom-
binant alpha-2b interferon and feline recombinant omega
interferon on in vitro replication of feline herpesvirus-1.
Am J of Vet Res. 8, 1406-1411.
- Tan Q, Zhu Y, Li J, Chen Z, Han GW, Kufareva I, Li T,
Ma L, Fenalti G, Li J, Zhang W, Xie X, Yang H, Jiang H,
Cherezov V, Liu H, Stevens RC, Zhao Q, Wu B, (2013).
Structure of the CCR5 Chemokine Receptor–HIV Entry
Inhibitor Maraviroc Complex. Sci. 341, 1387-1390.
- Thomasy SM, Maggs DJ, (2016). A review of antiviral
drugs and other compounds with activity against feline
herpesvirus type 1. Vet Ophthalmol. 19, 119-130.
- Tözsér J, (2010). Comparative Studies on Retroviral
Proteases: Substrate Specificity. Viruses. 2, 147-165.
- Wensing AM, Van Maarseveen NM, Nijhuis M, (2010).
Fifteen years of HIV protease inhibitors: raising the bar-
rier to resistance. Antiviral Res. 85, 59–74.
- . Wilhelmus KR, (2015). Antiviral treatment and other thera-
peutic interventions for herpes simplex virus epithelial ker-
atitis. Cochrane Database Syst Rev, 8, CD002898.
- Yamada H, İkushima İ, Nemato T, İshikawa T, Ninomiya
N, İrie S, (2017). Effects of a nutritional protein-rich drink
on the pharmacokinetics of elvitegravir, cobicistat, emtric-
itabine, tenofovir alafenamide, and tenofovir compared
with a standard meal in healthy japanese male subjects.
Clin Pharma Drug Develop. 7, 132-142.